Graded claim

CBG and antibacterial activity

What does the evidence show for CBG and bacterial infection (MRSA)?

In laboratory (in vitro) tests and in a mouse infection model, CBG showed activity against methicillin-resistant Staphylococcus aureus (MRSA), including effects on the bacterial membrane and biofilms. These are preclinical findings only — not tested in humans, and not evidence of benefit as an anti-infective.

grade: Lowpreclinical only
What reaching the next rung would take

Any one of these, on top of what our registry already holds:

  • one animal (preclinical) effect study from a research group not already counted here
  • one human trial of any size — including a small, short (acute / single-dose) one

The grade weighs the claim as a whole, across every study our registry holds on the question. How good any one of those papers is remains a separate matter, and you can judge each on its own terms.

Permalink

Studies behind this grade

2008

Antibacterial cannabinoids from Cannabis sativa: a structure-activity study

Appendino et al. · Journal of Natural Products · PMID 18681481 · study type: In vitro

in vitro (MIC vs MRSA strains) · in-vitro

PubMed →
2020

Uncovering the Hidden Antibiotic Potential of Cannabis

Farha et al. · ACS Infectious Diseases · PMID 32017534 · study type: Animal · preclinical

preclinical (in vitro + murine systemic-infection model) · animal

PubMed →

Other conditions we cover

The CBG monograph covers the compound end to end, and the gap-map charts the questions nobody has tested yet.

CBG acts on α2-adrenoceptors, which help regulate blood pressure; anyone taking cardiovascular medication should consult a clinician before using CBG products. Nothing on this page is medical advice, and no statement here is a claim that CBG treats, cures, or prevents any condition. Grades are based on the studies we had checked as of 9 August 2026. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.